

FROZEN IMMUNODEPLETED DEFICIENT PLASMAS

INTRINSIC PATHWAY

FACTOR VIII

FROZEN IMMUNODEPLETED DEFICIENT PLASMAS

Fresh frozen plasmas

CRYOcheck™ Factor VIII Deficient Plasma



Associated products

CRYOcheck™ Abnormal 1 Reference Control

CRYOcheck™ Abnormal 2 Reference Control

CRYOcheck™ Factor IX Deficient Plasma

CRYOcheck™ Factor XI Deficient Plasma

CRYOcheck™ Factor XII Deficient Plasma

CRYOcheck™ Normal Reference Plasma

CRYOcheck™ Prekallikrein Deficient Plasma

CRYOcheck™ Reference Control Normal

Fitzgerald Trait Plasma

Very Low VIII Control Plasma

Reference	Presentation	Format	Number of tests
FDP08-10	Kit	25 x 1.0 mL	500
FDP08-15	Kit	25 x 1.5 mL	750

Plasma deficient for factor VIII assay.

CRYOcheck™ Factor VIII Deficient is a frozen plasma, immuno-depleted, poor in platelets and certified to have less than 1% factor VIII.

Components

- 25 cryotubes x 1 mL or 1.5 mL of frozen plasma

Advantages

- CE adaptation on many analyzers on the market
- Technical validation file
- Reserved lots
- Precise rates indicated in the certificate of analysis for all factors
- Ready to use

Characteristics

CRYOcheck™ Factor Deficient Plasma consist of pools of citrated human normal plasmas which have been depleted into a coagulation factor by immunoadsorption, buffered with HEPES buffer, aliquoted and frozen rapidly.

- Certificate of analysis supplied with each batch.
- Expiration date of 3 years from the date of manufacture with storage between -40 °C and -80 °C
- The other factors have been tested and the results are provided on the Certificate of Analysis that accompanies each lot number.
- Contains no inhibitor, suitable for research of inhibitors (Bethesda or Nijmegen)
- It is deficient both for antigenic assay and functional in hemostasis.



Informations

Factor VIII is a glycoprotein mainly synthesized by the liver. It circulates in the plasma in the form bound to VWF which protects it from rapid proteolytic degradation.

It is activated by FXa or thrombin in FVIIIa which will complex with FIXa in the presence of phospholipids to activate FX in FXa. A patient who is deficient in FVIII has hemophilia A.

